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OBJECTIVES: To assess the impact of vasopressin on the microcirculation and to develop a predictive model to
estimate the probability of microcirculatory recruitment in patients with septic shock.
METHODS: This prospective interventional study included patients with septic shock receiving noradrenaline for
less than 48 hours. We infused vasopressin at 0.04 U/min for one hour. Hemodynamic measurements, including
sidestream dark-field imaging, were obtained immediately before vasopressin infusion, 1 hour after vasopressin
infusion and 1 hour after vasopressin withdrawal. We defined patients with more than a 10% increase in total
vascular density and perfused vascular density as responders. ClinicalTrials.gov: NCT02053675.
RESULTS: Eighteen patients were included, and nine (50%) showed improved microcirculation after infusion of
vasopressin. The noradrenaline dose was significantly reduced after vasopressin (p=0.001) and was higher both
at baseline and during vasopressin infusion in the responders than in the non-responders. The strongest
predictor for a favorable microcirculatory response was the dose of noradrenaline at baseline (OR=4.5; 95% CI:
1.2-17.0; p=0.027). For patients using a noradrenaline dose higher than 0.38 mcg/kg/min, the probability that
microcirculatory perfusion would be improved with vasopressin was 53% (sensitivity 78%, specificity 77%).
CONCLUSIONS: In patients with septic shock for no longer than 48 h, administration of vasopressin is likely to result
in an improvement in microcirculation when the baseline noradrenaline dose is higher than 0.38 mcg/kg/min.
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’ INTRODUCTION
In patients with septic shock, noradrenaline is usually
administered to achieve an adequate mean arterial pressure
(MAP) to maintain sufficient organ perfusion. However,
adrenergic receptors are hyposensitive during the advanced
stages of septic shock (1,2), and the use of a high nor-
adrenaline dose in these circumstances is associated with
adverse events (3-6). Excessive use of adrenergic drugs is
associated with not only undesirable hemodynamic effects
but also enhanced coagulation, reduced innate and adap-
tive immunity and increased bacterial replication and
virulence (7). Thus, the rationale for developing strategies
aiming to sparingly use catecholamines in critically ill patients
is strong.
Vasopressin has been used as an adjunct to noradrenaline
for severe hypotension. A previous meta-analysis of rando-
mized trials suggested improved survival in patients with
septic shock who received vasopressin (8-10), although a
recent study failed to show improvement in renal dysfunc-
tion (11). In addition, several studies have demonstrated that
adding vasopressin to a noradrenaline infusion decreases
catecholamine requirements (12-17).
Microcirculatory alterations are a hallmark of sepsis, are
associated with outcomes (18-20) and are stronger predictors
than global hemodynamic variables (21). The effects of vaso-
pressin on the microcirculation have not been adequately
studied. The strong vasoconstrictive action, which might
hamper microcirculatory flow, of vasopressin is a focus of
concern (22). However, the effects of vasopressin on V1
receptors in combination with the reduced dose of adrenergic
vasopressors could potentially lead to improved perfusion at
the microcirculatory level despite potential negative effects on
macrocirculatory parameters such as cardiac output (23-26).DOI: 10.6061/clinics/2017(12)06
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Based on these observations, we carried out a prospective
study to evaluate the effects of vasopressin on microcircu-
latory parameters. In addition, we assessed potential predic-
tive factors related to microcirculation recruitment by vasopressin
in septic patients using noradrenaline to sustain MAP.
’ MATERIALS AND METHODS
Study population
This prospective study was conducted in a 35-bed inten-
sive care unit of a teaching hospital. Between June 2010 and
August 2012, we included patients with septic shock who
received adrenergic vasopressors for less than 48 hours and
were monitored with an arterial catheter and a pulmonary
artery catheter because we required the monitoring of the
cardiac index (CI). According to the unit protocol, in the absence
of contraindications, patients with septic shock using noradre-
naline above 0.3 mcg/kg/min during the first 24 hours of shock
were monitored with a pulmonary artery catheter. Sepsis was
defined according to the Society of Critical Care Medicine-
American College of Chest Physicians Consensus Conference
(27). Septic shock was defined as fluid-refractory hypotension
requiring vasopressors with no requirement of elevated lactate
levels because the study was conducted before the new
definition of septic shock (28). Exclusion criteria included the
following: use of vasopressin; acute coronary disease; suspected
or confirmed acute mesenteric ischemia; severe hyponatremia
(Na+o130mmol/L); Raynaud’s phenomenon; systemic sclerosis;
pregnancy; or a technical difficulty preventing sublingual video
microscopy. The study was conducted according to the
Helsinki Declaration, which was revised in 1983, and accord-
ing to the Resolution 196/96 of the Conselho Nacional de
Saude. The Research and Ethics Committee of the institution
approved study number 2081/08, and all patients or their
legal representatives provided informed consent. Clinical-
Trials.gov: NCT02053675.
Measurements
The demographic and sepsis characteristics and the severity
scores from the APACHE II and SOFAwere recorded. Hemo-
dynamic measurements included semi-continuous thermo-
dilution CI (Vigilance, Edwards LifeSciences, Irvine, CA,
USA), heart rate (HR), MAP, central venous pressure (CVP),
pulmonary arterial pressure (PAP), and pulmonary arterial
occlusion pressure (PAOP). Ventilator settings were recorded
and arterial and mixed venous blood were collected for
blood gases analysis, oxygen venous saturation (SvO2) and
serum lactate.
We assessed sublingual microcirculation using sidestream
dark-field (SDF) imaging (Microscan, MicroVision Medical,
Amsterdam, Netherlands). To ensure image quality, a skilled
physician using the recommended techniques obtained all of
the images (29). Three high-quality steady images of at least
20 seconds on both sides of the tongue were obtained while
avoiding pressure artifacts. All images were captured using a
portable computer and an analog/digital video converter.
Microcirculatory parameters, including the microcirculatory
flow index (MFI), total vascular density (TVD), proportion
of perfused vessels (PPV), perfused vascular density (PVD)
and heterogeneity index (HI) (29), were analyzed using AVA 3.0s
software (MicroVision Medical, Amsterdam, Netherlands).
We obtained only images that were related to vessels with
diameters less than 20 mm. We assigned a random number to
each image, and the investigator (A.P.M.N.) who analyzed
the images was blinded to the patients and details associated
with the images.
Study protocol
Immediately before vasopressin infusion, each patient was
evaluated for adequate intravascular volume as evidenced
by pulse pressure variation assessment (DX 2020, Dixtal,
São Paulo, Brazil) after adequate continuous sedation to
control spontaneous ventilatory efforts. Patients with a pulse
pressure variation 413% received repeated Ringer’s lactate
challenges until the pulse pressure variation was below this
value. Patients with pulse pressure variations that could not
be measured received fluid challenges until no increase in
cardiac output greater than 10% was evident. Vasopressors
were used to maintain MAP above 65 mmHg. The oxygen
inspiratory fraction was adjusted to maintain peripheral
oxygen saturation above 92%.
Thirty minutes after the initial stabilization, we obtained
the baseline hemodynamic, respiratory, and sublingual micro-
circulatory measurements (T0). After the baseline measure-
ments, vasopressin was administered at a fixed dose of
0.04 U/min. One hour after vasopressin infusion, we collected
the data from the same variables (T1). Vasopressin was stop-
ped, and new measurements were recorded after 1 hour (T2).
If clinically required, the vasopressor infusion was adjusted
during the study period to maintain a target MAP level
465 mmHg. If the patients received dobutamine, the doses
were kept constant during the study procedure. Patients were
excluded from the study if there was a clinical indication of
tapering of the ventilator parameters or additional sedation
during the intended study period.
Statistical analysis
Data are expressed as the mean±standard deviation,
median [interquartile range], or frequency (n, %), as appro-
priate. The time points of the study were defined as T0
(baseline before vasopressin infusion), T1 (one hour after
vasopressin infusion), and T2 (one hour after cessation of
vasopressin infusion). The Shapiro-Wilk test and stratified
distribution plots were used to verify the normality of the
distribution of continuous variables. All quantitative data
were normally distributed except for the doses of noradrena-
line and lactate. Data that were not normally distributed
underwent log transformation to achieve close to normal
distribution and were then qualified for longitudinal testing.
We categorized patients as responders and non-responders
based on changes to sublingual vascular density. Because
visible obstructed capillaries do not change TVD but have
effects on PVD, we defined responders as those who pre-
sented a more than a 10% increase in TVD or PVD after
vasopressin infusion. This cut-off was based on a previous
study showing that slight changes in the microcirculation are
associated with the degree of organ dysfunction (30). Factors
associated with the microcirculation response were analyzed
using a multivariate regression analysis to develop the pre-
dictive model for improvement in microcirculation. Relevant
candidate predictor variables at baseline were selected for
possible inclusion in the model, including TVD, noradrenaline
dose, MAP, HR, CVP, lactate and CI. A backward-elimination
approach was tested with all variables, and hypothesis
tests were sequentially applied to determine which vari-
ables would be removed from the final model. (Predictors
were removed if the significance level was more than 0.10.)
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Discriminative ability was determined with the c-statistic, which
is equivalent to the area under the receiver operator character-
istic (ROC) curve. The results were then summarized in a
graphical assessment of the expected probability for a micro-
circulatory response based on the final model.
The statistical comparisons at each time point of the study
were performed using a generalized mixed-model analysis
to estimate the mean response differences and significance
of the covariates (global hemodynamic variables and sub-
lingual microcirculation parameters) within the time points
(factor) between responders and non-responders (dependent
variable). The interaction was tested for each time point
to investigate the relationship between changes in hemo-
dynamic variables (MAP, CVP and CI) and microcirculatory
parameters. SPSS (version 23.0, SPSS, Chicago, IL, USA) was
used for statistical analyses. A p-valueo0.05 was considered
to be statistically significant.
’ RESULTS
We screened 116 patients with septic shock who were admit-
ted to the intensive care unit. Fifty-one patients were not
included because SDF or the study team were not available.
Other reasons for non-eligibility included the following:
absence of a Swan-Ganz catheter (n=27), reversal of shock
before the baseline assessment (n=10), lack of informed consent
(n=3), acute coronary disease (n=2), use of norepinephrine
longer than 48 hours (n=2), previous use of vasopressin (n=1),
pregnancy (n=1) and death before inclusion (n=1). Eighteen
consecutive patients with septic shock were included in the
study. Their characteristics at baseline are listed in Table 1.
The patients received adrenergic vasopressors for a mean of
27.2±12.2 hours, and the hospital mortality rate was 72%. All
patients received 0.04 U/min of vasopressin for one hour,
except for one patient who received a dose of 0.02 U/min. At
baseline, only four patients received epinephrine (mean dose,
0.28±0.08 mcg/kg/min), and five patients received dobuta-
mine (mean dose, 5.6±2.9 mcg/kg/min). For most patients,
we did not change these medication doses; however, for one
patient we reduced the epinephrine dose from 0.26 mg/kg/min
to 0.13 mg/kg/min instead of reducing the noradrenaline dose
because an increase in MAP and excessive tachycardia were
evident. In 3 patients, an assessment of the T2 measurement
was not possible because there was a clinical indication of
tapering of the ventilator parameters or additional sedation.
After vasopressin infusion, the absolute mean reduc-
tion in the norepinephrine infusion rate was 32.2±27.4%;
p=0.001. Nine patients showed improvements in microvascular
density after 1 hour of vasopressin infusion. Tables 2 and 3
show the hemodynamic and sublingual microcirculation
parameters, respectively, which are stratified by responders
and non-responders. Both responders and non-responders
had a significant decrease in the noradrenaline dose during
the infusion of vasopressin, whereas the noradrenaline dose
was significantly higher in the responders than the non-
responders both at baseline and during vasopressin infusion
(Table 2). Only 5 patients were using dobutamine at baseline;
2 were responders, and 3 were non-responders. After dis-
continuation of the vasopressin infusion, the noradrenaline
dose increased significantly in the non-responder group only,
Table 1 - Demographic data and sepsis characteristics.
Variable All patients (n=18) Responders (n=9) Non-responders (n=9) p value
Age (years) 62.3±17.8 63.9±17.4 60.2±19.8 0.601
Males 11 (61.1) 6 (66.7) 5 (55.6) 0.629
APACHE II 13.4±4.6 14.1±6.1 12.9±3.1 0.630
Admission SOFA 11 (8, 13) 10 (7, 12.5) 11 (9.5,13)
Admission category 0.881
Ward 7 (38.9) 4 (44.4) 3 (33.3)
Surgery 9 (50) 4 (44.4) 5 (55.6)
Emergency department 2 (11.1) 1 (11.1) 1 (11.1)
Patient category 0.774
Medical 9 (50) 5 (55.6) 4 (44.4)
Elective surgical 3 (16.7) 2 (22.2) 1 (11.1)
Emergency surgical 6 (33.4) 2 (22.2) 4 (44.4)
Type of infection 0.287
Community 5 (27.8) 1 (11.1) 4 (44.4)
Nosocomial - ward 8 (44.4) 5 (55.6) 3 (33.3)
Nosocomial - ICU 5 (27.8) 3 (33.3) 2 (22.2)
Site of infection 0.164
Lung 5 (27.8) 2 (22.2) 3 (33.3)
Abdominal 6 (33.3) 2 (22.2) 4 (44.4)
Urinary 2 (11.1) 0 (0) 2 (22.2)
Catheter 1 (5.6) 1 (11.1) 0 (0)
Bloodstream 2 (11.1) 2 (22.2) 0 (0)
Unknown 2 (11.1) 2 (22.2) 0 (0)
Organ dysfunctions (number) 4.17±1.61 3.78 ±1.4 4.56±1.8 0.322
Duration of organ dysfunction (hours) 36.54 (30.0, 51.8) 39.9 (29.7, 56.5) 34.7 (27.7, 45.4) 0.606
Duration of vasopressor use (hours) 27.2±12.2 24.7±13.8 29.3±10.9 0.457
ICU mortality 11 (61.1) 6 (66.7) 5 (55.6) 0.629
Hospital mortality 13 (72.2) 6 (66.7) 7 (77.8) 0.599
APACHE, Acute Physiological Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; ICU, intensive care unit. The results are expressed as
the number (%), mean±standard deviation or median (25%, 75%).
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Table 2 - Global hemodynamic parameters and noradrenaline dose recorded at the three different time points during the study
protocol and categorized according to responders and non-responders.
Variables Subgroup T0 (n=18) T1 (n=18) T2 (n=15)
Noradrenaline (mg/K/min) Non-responder 0.28 (0.17-0.41) 0.15 (0.09-0.24)* 0.39 (0.23-0.56)*
Responder 0.68 (0.40-1.04) 0.49 (0.38-0.88)* 0.59 (0.42-0.88)
p value 0.008 0.010 0.320
HR (bpm) Non-responder 101 (12) 96 (14)* 101 (11)*
Responder 113 (25) 109 (23) 116 (20)*
p value 0.220 0.150 0.060
MAP (mmHg) Non-responder 74.6 (8) 74.4 (5) 70.1 (5)
Responder 70.4 (3) 70.8 (3) 70.5 (4)
p value 0.152 0.089 0.370
CI (L/min.m2) Non-responder 4.5 (1.28) 3.6 (1.04)* 4.0 (0.96)*
Responder 4.2 (1.20) 3.7 (0.91) 3.9 (0.82)
p value 0.560 0.900 0.510
SI (mL/m2) Non-responder 45.2 (15.2) 38.8 (12.9) 40.5 (11.5)
Responder 36.4 (7.1) 34.6 (7.2) 34.7 (7.9)
p value 0.146 0.405 0.262
Lactate (mg/dL) Non-responder 21.3 (14.0-32.0) 18.9 (12.9-27.1) 25.0 (12.9-43.8)
Responder 30.8 (24.0-43.8) 28.7 (21.9-46.0) 27.1 (23.1-32.1)
p value 0.22 0.15 0.23
SvO2 (%) Non-responder 71.4 (6.9) 69.1 (9.5) 73.3 (8.8)
Responder 75.7 (5.7) 72.5 (5.4) 71.7 (5.4)*
p value 0.170 0.360 0.450
a-vCO2 Non-responder 3.0 (1.3) 4.8 (1.6) 4.6 (2.0)
Responder 4.1 (2.2) 5.5 (3.9) 4.8 (1.3)
p value 0.28 0.44 0.85
DO2 (mL/min) Non-responder 791 (673-1435) 739 (568-986)* 731 (542-1231)
Responder 836 (678-1080) 738 (613-955) 740 (673-1116)
p value 0.51 0.89 0.70
VO2 (mL/min) Non-responder 188 (152-370) 171 (132-292)* 188 (156-278)*
Responder 197 (145-243) 199 (145-206) 196 (173-221)
p value 0.19 0.42 0.29
Extraction rate (%) Non-responder 25.6 (21-26) 23.1 (19-34) 23.3 (21-35)
Responder 22.0 (18-31) 22.6 (18-28) 23.7 (17-29)
p value 0.49 0.29 0.39
Time points are defined as before (T0), during (T1) and after (T2) vasopressin infusion. There were 9 responders and 9 non-responders. HR, heart rate;
MAP, mean arterial pressure; CI, cardiac index; SI, systolic index; SvO2, oxygen mixed venous saturation. Data are expressed as the mean (standard
deviation) or median (25%, 75%).
*po0.05 vs. previous time point within the same group.
Table 3 - Sublingual microcirculation parameters recorded at the three different time points during the study protocol and
categorized according to responders and non-responders.
Variable Subgroup T0 T1 T2
TVD (mm/mm2) Non-responder 15.9 (2.5) 14.4 (1.8)* 14.8 (0.58)
Responder 14.3 (1.7) 16.3 (1.6)* 15.2 (1.57)*
p value 0.13 0.03 0.35
PVD (mm/mm2) Non-responder 13.9 (2.7) 12.4 (1.8)* 12.6 (1.3)
Responder 12.1 (1.9) 14.4 (1.4)* 13.0 (1.9)*
p value 0.11 0.02 0.47
PPV (%) Non-responder 87.3 (7.6) 86.5 (6.4) 85.0 (7.8)
Responder 83.5 (6.0) 89.0 (4.8)* 86.6 (7.0)
p value 0.26 0.36 0.62
MFI Non-responder 2.7 (0.2) 2.8 (0.2) 2.7 (0.2)
Responder 2.7 (0.1) 2.6 (0.3) 2.7 (0.2)
p value 0.69 0.15 0.89
Time points are defined as before (T0), during (T1) and after (T2) vasopressin infusion. There were 9 responders and 9 non-responders. TVD, total vascular
density; PPV, proportion of perfused vessels; PVD, perfused vascular density; MFI, microcirculatory flow index; Data are expressed as the mean (standard
deviation) or median (25%, 75%).
*po0.05 vs. previous time points within the same group.
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and both responders and non-responders received similar
noradrenaline doses at that time. According to our interac-
tion analysis in the generalized mixed-model, the changes in
CI, MAP and CVP had no significant effects on TVD or PVD.
Interestingly, the decrease in noradrenaline dosing in the
non-responder group was associated with a decrease in CI,
oxygen delivery (DO2) and oxygen consumption (VO2),
whereas CI was restored to baseline levels after discontinua-
tion of the vasopressin and the subsequent increase in
noradrenaline dosing to maintain MAP (Table 2). The hemo-
dynamic parameters, laboratory variables and microcircula-
tory measurements in the whole population obtained before
and after the vasopressin infusion are listed in the electronic
supplementary material (Table S1 and S2).
In a multivariate regression model (Table S3), the strongest
predictor for an improvement in the microcirculation
was the baseline dose of noradrenaline (OR=4.5; 95% CI:
1.2-17.0; p=0.027). Figure 1 shows the probability of a
microcirculatory response based on the noradrenaline dose.
The model showed adequate calibration, good discrimina-
tion and an area under the ROC curve of 0.85 (95% CI:
0.66-0.99). The probability for 78% sensitivity is indicated,
which corresponds to a predicted probability of more than
50% for patients receiving a noradrenaline dose higher than
0.38 mcg/kg/min (log scale 4-0.97 in the graph). Table 4
shows the final model with predicted probabilities for a
microcirculatory response to vasopressin according to different
infusion doses of noradrenaline to facilitate practical
application.
’ DISCUSSION
The primary finding of this study was that the improve-
ment in the microcirculatory parameters after vasopressin
infusion in the septic shock patients was highly associated
with the level of noradrenaline dependency and was inde-
pendent of systemic hemodynamic parameters (CI, MAP,
and CVP). This finding suggests that the patient’s noradrena-
line dose is directly proportional to the likelihood that
the patient will respond to vasopressin infusion. For clinical
decision making, patients receiving a noradrenaline dose above
0.38 mcg/kg/min (independent of hemodynamic conditions)
Figure 1 - Probability of microcirculatory response based on a dose of noradrenaline at T0 (logarithmic scale). The dotted line shows the
threshold value of the predicted probability of 53% for patients receiving a noradrenaline dose higher than 0.38 mcg/kg/min (78%
sensitivity and 77% specificity).
Table 4 - Predicted probability of the different doses of
noradrenaline for microcirculatory responses with their
corresponding sensitivity and specificity.
Noradrenaline
dose
(mcg/kg/min)
Predicted probability for
the microcirculatory
response to vasopressin
Sensitivity* Specificity*
40.17 27.8% 89% 56%
40.38 53.0% 78% 77%
40.68 77.6% 67% 99%
*ROC curve, AUC = 85%, p=0.013.
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are candidates for vasopressin use with a 53% probability of
recruiting the microcirculation. These findings, which were not
previously reported, may help with selecting patients who may
benefit from the association of vasopressin according to their
noradrenaline dependency status.
The effects of vasopressin in the microcirculation have
already been demonstrated by Morelli’s group, which showed
that continuous infusions of low-dose vasopressin and terli-
pressin improved the MFI after 6 hours. However, the authors
found similar results in the control group, which suggests that
these changes may not have been related to vasopressin use
(31). In our study, we assessed only the short-term effects of
vasopressin. Although a subgroup analysis of the VASST study
has suggested that patients with less severe septic shock, who
require 5 to 14 mcg of noradrenaline per minute, would have
better clinical outcomes with the use of vasopressin (32) at the
microcirculatory level; however, our results point in the oppo-
site direction. Our multivariate model showed that the most
clinically useful predictor for a microcirculatory response was
the noradrenaline dose required to maintain a MAP above
65 mmHg. Vasopressin infusion also reduced norepinephrine
requirements without any significant adverse effect during this
short period of infusion.
Microcirculatory alterations can be observed even when
systemic hemodynamics are within satisfactory goals. The
independence of the microcirculation parameters has been
previously reported (18) (33) (34,35). However, microcircu-
latory perfusion can be affected by cardiac output and arterial
pressure when these variables are critically altered. We found
that non-responders had a significant reduction in their cardiac
output, DO2 and VO2 during vasopressin infusion, which
suggests that changes in the systemic hemodynamics may
lead to microcirculatory alterations. However, the reduction
in DO2 was not followed by an increase in arterial lactate or
differences in other tissue perfusion parameters, suggesting that
these macrohemodynamic alterations were not clinically rele-
vant. However, changes in the CI were not associated with
improvement in the microcirculation in our multivariate model.
This result highlights the relevance of measuring CI in studies
aiming to assess microcirculation even if the enrollment rate is
compromised. In fact, one of the major reasons for not enrolling
patients in our study was the absence of CI measurements.
Additionally, the reduction in CI may have been related to
the reduction in the noradrenaline dose and, consequently, to
its inotropic and chronotropic effects or its effect on venous
return. A non-significant reduction in the SI was evident
during vasopressin infusion. The reduction in noradrenaline
dose might be considered a beneficial effect as increasing
evidence indicates that the excessive use of catecholamines is
associated with potential iatrogenic complications. These
potential harmful effects are not exclusively related to well-
known hemodynamic effects, namely, increased energy expendi-
ture; excessive vasoconstriction; and splanchnic hypoperfusion
with altered gut motility, function and potential bacterial trans-
location. Convincing evidence exists showing that the phago-
cytic capacity of macrophages and neutrophils is inhibited (36),
together with lymphopenia and a shift toward a Th2 pattern
(37). Bacterial virulence and proliferation is also enhanced (7).
Metabolic changes include hyperglycemia, hypertriglyceride-
mia and thyroid hormone alterations. Coagulation disorders
with enhanced clot formation and a reduction in fibrinolysis
have also been reported (7). Thus, the use of vasopressin is part
of the decatecholaminization strategy that has gained increased
support in critical care.
Although our study was not designed to assess causality,
we can provide several hypotheses. Vasopressin led to a
reduction in the noradrenaline dose in all patients. This result
suggests that the use of receptors other than adrenergic
receptors will lead to a better response in vasopressor tone
and, consequently, to a reduction in the need for vasopres-
sors. Reducing the excessive vasopressor effect of noradrena-
line may have led to an increase in microcirculatory density
and perfusion in the responders. Non-responders were using
a smaller dose of noradrenaline, which suggests less severe
disease and vasodilation. In this context, vasopressin might
have caused excessive vasoconstriction, as suggested by
the finding of a decrease in PVD. Moreover, the potential
negative effects of vasopressin in cardiac output may have
played a role. Patients who had a smaller reduction in CI
after vasopressin infusion would be likely to show improve-
ments in microcirculation. The differences between the respon-
ders and non-responders regarding the impact of vasopressin
on CI, DO2 and VO2 were interesting. For the non-responders,
the CI reduction did not compromise the microcirculation but
was associated with a decrease in VO2 that was reversed
when vasopressin was suspended. This finding hypothetically
suggests that if vasopressin is used, a decrease in noradrena-
line requirements may occur if the microcirculation does not
improve the overall effect of vasopressin, which might be
harmful. However, these notions are speculations because
distinguishing the effects of vasopressin on contractility from
its vasoconstrictive effects on microcirculation is difficult.
Although this study provides novel observations, a fixed
dose of vasopressin was used, which could be considered
insufficient to show any beneficial or harmful effects. A pre-
vious study suggested that a higher dose of vasopressin
(0.067 U/min) would restore hemodynamics more effectively
and that the dose was not associated with a high incidence of
adverse effects (38). Another limitation of the present study
is the absence of a control group. However, this study was
designed to allow every patient to serve as his or her own
control, which minimizes bias. Therefore, the significant
improvement or decrease in the sublingual microcirculation
parameters during and after vasopressin infusion strengthens
our findings. An additional limitation is the short observation
period of our study as a longer AVP infusion period might
have a different impact on the microcirculatory response.
Notably, the high severity of illness in our population is
another limitation worth considering. These patients had a
mean organ dysfunction incidence of 4.2 and a high mortality
rate. Thus, the effects of vasopressin may be different in
patients with a less severe shock.
In conclusion, the clinical monitoring of the sublingual
microcirculation can help identify patients with septic shock
that might benefit from the association of vasopressin. Our
results suggest that a noradrenaline dose above 0.38 mcg/
kg/min might be a good predictor for the microcirculatory
response to the vasopressin infusion. Additional research
that explores different microcirculatory beds and uses dif-
ferent measurement tools for assessing microcirculation will
improve our knowledge concerning the role of vasopressin
in septic shock resuscitation.
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’ APPENDIX
Table S1 - Changes in hemodynamic, respiratory and metabolic variables after vasopressin infusion – global analysis.
Variables T0
(n=18)
T1
(n=18)
T2
(n=15)
Norepinephrine (mg/kg/min) 0.41 (0.23, 0.90) 0.31 (0.09, 0.76)* 0.56 (0.23, 0.85)*
Heart rate (bpm) 107.4±19.7 102.7±19.9* 110.53±18.9*
MAP (mmHg) 72.56±6.2 72.7±4.4 70.4±4,0
CVP (mmHg) 11.6±5.0 11.8±4.6 11.5±4.5
PAOP (mmHg) 9.6±4.5 10.6±3.7 9.0±4.2
mPAP (mmHg) 27.6±8.0 26.9±7.4 26.7±7.5
CO (L/min) 7.8±2.9 6.7±2.4* 7.1±2.2*
CI (L/min.m2) 4.4±1.2 3.7±0.9* 4.0±0.8*
SI (ml/beat/m2) 40.8±12.4 36.9±10.6 37.0±9.6
PPV (%) 5.0 (3.0, 10.5) 4.0 (2.1, 8.7) 4.7 (4.0, 5.7)
DO2 (ml/min) 813.5 (676.2, 1153.0) 738.5 (595.5, 939.5)* 740.0 (643.0, 1048.0)
VO2 (mL/min) 188.0 (142.0, 246.0) 171.0 (140.0, 203.0)* 196.0 (164.0, 225.0)*
Extraction rate (%) 24.6±7.1 25.6±7.9 25.0±7.1
PEEP (cmH2O) 9.6±3.6 9.6±3.6 9.5±3.9
FiO2 (%) 0.40 (0.40, 0.50) 0.40 (0.40, 0.50) 0.4 (0.4, 0.5)
pO2/FiO2 ratio 231.2 (169.4, 263.5) 222.5 (187.6, 255.7) 203.0 (185.0, 231.0)
Lactate (mg/dL) 30.3±17.3 27.6±15.8 29.6±15.4
a-vCO2 (mmHg) 3.7 (2.5, 4.7) 4.6 (3.2, 6.5) 4.7 (4.0, 5.7)
Urine output (ml/kg/h) 0.2 (0.0, 1.4) 0.1 (0.0, 0.4) 0.0 (0.0, 0.5)
SvO2 (%) 73.6±6.5 70.9±7.7 72.4±6.7
Haemoglobin (g/dL) 9.0±1.4 8.8±1.4 8.8±1.5
Time points are defined as before (T0), during (T1) and after (T2) vasopressin infusion. MAP, mean arterial pressure; CVP, central venous pressure; PAOP,
pulmonary artery occluded pressure; PAP, pulmonary artery pressure; CO, cardiac output; CI, cardiac index; SI, systolic index; PPV, pulse pressure variation;
DO2, oxygen delivery; PEEP, positive end expiratory pressure; FiO2, fraction of inspired oxygen; pO2, oxygen partial pressure; DCO2, venous-arterial CO2
gradient; SvO2, oxygen mixed venous saturation. Data are expressed as number (%), mean±standard deviation or median (25%, 75%).
*po0.05 vs. previous time point.
Table S2 - Changes in the microcirculatory variables after vasopressin infusion – global analysis.
Variable T0 T1 T2
TVD (mm/mm2) 15.1± 2.2 15.2±1.8 15.2±1.5
PVD (mm/mm2) 13.0±2.4 13.4±1.8 12.9±1.7
PPV (%) 87.1 (83.0, 90.5) 88.6 (84.1, 90.5) 85.8 (83.4, 90.5)
MFI 2.7 (2.6, 2.9) 2.9 (2.5, 3.0) 2.7 (2.5, 3.0)
Time points are defined as before (T0), during (T1) and after (T2) vasopressin infusion. TVD, total vascular density; PPV, proportion of perfused vessels;
PVD, perfused vascular density; MFI, microcirculatory flow index; HI, heterogeneity index. Data are expressed as mean±standard deviation or median
(25%, 75%).
*po0.05 vs. previous time point.
Table S3 - Multivariable regression model to changes in microcirculatory response.
Independent variable b coefficient±SE OR 95% CI p-value
TVD -0.73±0.4 0.479 (0.180 – 1.272) 0.14
HR 0.013±0.07 1.013 (0.877 – 1.172) 0.85
MAP -0.15±0.31 0.855 (0.463 – 1.579) 0.61
CVP 0.09±0.34 1.104 (0.566 – 2.154) 0.77
Lactate -0.07±0.068 0.925 (0.811 – 1.056) 0.25
CI -0.83±0.81 0.433 (0.088 – 2.128) 0.30
Noradrenaline dose* 4.8±2.3 5.611 (1.130 – 27.861) 0.03
*Noradrenaline dose was used as a categorized variable.
Backward-elimination approach was tested and predictors were removed if significance level were more than 0.10. Independent variables at baseline
were included: Total Vascular Density (TVD), hear rate (HR), mean arterial pressure (MAP), central venous pressure (CVP), lactate, cardiac index (CI) and
noradrenaline dose.
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